Table of Contents
Lung Cancer International
Volume 2012, Article ID 729532, 12 pages
Review Article

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer

Laboratory of Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre, Kerala, Trivandrum 695011, India

Received 29 May 2012; Revised 3 August 2012; Accepted 23 August 2012

Academic Editor: Elisabeth Quoix

Copyright © 2012 Alphy Rose-James and Sreelekha TT. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lung cancer accounts for the majority of cancer-related deaths worldwide of which non-small-cell lung carcinoma alone takes a toll of around 85%. Platinum-based therapy is the stronghold for lung cancer at present. The discovery of various molecular alterations that underlie lung cancer has contributed to the development of specifically targeted therapies employing specific mutation inhibitors. Targeted chemotherapy based on molecular profiling has shown great promise in lung cancer treatment. Various molecular markers with predictive and prognostic significance in lung cancer have evolved as a result of advanced research. Testing of EGFR and Kras mutations is now a common practice among community oncologists, and more recently, ALK rearrangements have been added to this group. This paper discusses various predictive and prognostic markers that are being investigated and have shown significant relevance which can be exploited for targeted treatment in lung cancer.